Want to see XERS full AI Analyst Report?
Top Page
Xeris Pharmaceuticals
(NASDAQ:XERS)
Select Model
Select Model
Rating:61Neutral
Price Target:
$9.00
▲(2.97% Upside)
Action:Reiterated
Date:09/09/26
Overall score reflects improving operations and cash generation, but is held back by capital structure risk (negative equity with meaningful debt) and still-negative net earnings. Recent earnings-call updates (raised/tightened guidance, strong Recorlev growth, improving margins/EBITDA) provide a meaningful positive offset, while technicals are neutral-to-mildly constructive and valuation is weak due to negative earnings and no dividend.
Positive Factors
Strong revenue trajectory
Rapid revenue growth and tighter full-year guidance indicate broad commercial execution and improving demand across the portfolio. If sustained, this scale can strengthen operating leverage, support additional investment in the pipeline, and increase Xeris’s strategic relevance in specialty pharmaceutical markets.
Negative Factors
Fragile capital structure
High debt alongside negative equity leaves a limited capital cushion and reduces flexibility during operating setbacks. Leverage can constrain future investment choices, increase dependence on sustained cash generation, and make refinancing or other financing decisions more consequential over the coming quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong revenue trajectory
Rapid revenue growth and tighter full-year guidance indicate broad commercial execution and improving demand across the portfolio. If sustained, this scale can strengthen operating leverage, support additional investment in the pipeline, and increase Xeris’s strategic relevance in specialty pharmaceutical markets.
Read all positive factors
Xeris Pharmaceuticals (XERS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.56B
Dividend YieldN/A
Average Volume (3M)1.56M
Price to Earnings (P/E)―
Beta (1Y)1.15
Revenue Growth36.33%
EPS Growth54.68%
CountryUS
Employees435
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.10
Shares Outstanding182,320,310
10 Day Avg. Volume1,216,248
30 Day Avg. Volume1,557,497
Financial Highlights & Ratios
PEG Ratio-22.22
Price to Book (P/B)92.00
Price to Sales (P/S)4.32
P/FCF Ratio45.09
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$12.00Price Target Upside37.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)$387.25M
Xeris Pharmaceuticals Business Overview & Revenue Model
Company Description
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current por...
How the Company Makes Money
Xeris makes money primarily by selling its FDA-approved prescription medicines. Its key revenue stream is net product revenue generated from U.S. sales of Gvoke, Keveyis, and Recorlev, which are distributed through pharmaceutical channels (e.g., w...
Xeris Pharmaceuticals Earnings Call Summary
Earnings Call Date:Aug 06, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 05, 2026
Earnings Call Sentiment Positive
The call emphasized strong commercial momentum (notably Recorlev’s 81% YoY growth), improved profitability (86% gross margin, adjusted EBITDA +50% YoY), strategic wins (Keveyis patent protection, retirement of convertible notes) and material pipeline progress for XP-8121 (multiple patents, Phase III planned by year-end). Lowlights were largely manageable: a one-time non-cash GAAP charge of ~$31M, higher near-term SG&A and R&D investments to fund growth and XP-8121, earlier-year softness in Gvoke that has since rebounded, and some remaining timing/enrollment uncertainty around Phase III. Overall, positive commercial execution and balance sheet actions outweigh the near-term charges and increased investment cadence.Positive Updates
Record Quarterly Revenue and Strong YoY Growth
Total revenue of $92.1M and net product revenue of $91M in Q2 2026, representing year-over-year growth of ~29% (total revenue) and ~34% (net product revenue). First half revenue growth of 33% and company raised the bottom end of full-year 2026 guidance to $385M–$390M (tightened $5M range).
Negative Updates
One-Time GAAP Charge Related to Convertible Notes
A one-time non-cash GAAP re-measurement charge of approximately $31M was recognized in Q2 related to the convertible notes exchange agreement; management noted this does not impact adjusted EBITDA and expects no additional income statement charge in Q3.
Read all updates
Q2-2026 Updates
Positive
Negative
Record Quarterly Revenue and Strong YoY Growth
Total revenue of $92.1M and net product revenue of $91M in Q2 2026, representing year-over-year growth of ~29% (total revenue) and ~34% (net product revenue). First half revenue growth of 33% and company raised the bottom end of full-year 2026 guidance to $385M–$390M (tightened $5M range).
Read all positive updates
Company Guidance
Xeris raised the bottom end of its 2026 total revenue guidance and tightened the range to $385–$390 million (a $5M band), implying roughly 33% growth at the midpoint, backed by strong H1 performance and Q2 results: total revenue $92.1M (up 29% YoY), net product revenue $91M (up 34% YoY), Recorlev $56.8M (up 81% YoY, +$25.3M), Gvoke $22.5M (up ~8% sequentially), and Keveyis $11.7M. Q2 gross margin was ~86% (≈400 bps improvement YoY); Q2 R&D was $10.7M (+$2.6M YoY) and management expects R&D to rise ≈$25M vs. 2025; Q2 SG&A was $61M and full‑year SG&A is now expected to increase ≈$50M vs. 2025 (vs. prior ~$45M guidance). Adjusted EBITDA was $19.3M in Q2 (up $6.7M YoY, >50% growth) and is forecast to increase in absolute dollars for 2026; the company also eliminated $34M of convertible debt (saving ≈$3M annually) while taking a one‑time non‑cash remeasurement charge of ~ $31M in Q2, and expects H2 uplift from Recorlev expansion and seasonal Gvoke demand.Xeris Pharmaceuticals Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
38
Negative
Cash Flow
72
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 335.41M | 291.85M | 203.07M | 163.91M | 110.25M | 49.59M |
| Gross Profit | 279.54M | 238.43M | 166.24M | 135.27M | 87.61M | 36.27M |
| EBITDA | 16.41M | 12.71M | -13.99M | -23.73M | -69.31M | -113.67M |
| Net Income | -17.16M | 554.00K | -54.84M | -62.26M | -94.66M | -122.72M |
Balance Sheet | ||||||
| Total Assets | 411.90M | 383.53M | 323.06M | 322.60M | 344.52M | 304.36M |
| Cash, Cash Equivalents and Short-Term Investments | 121.75M | 111.04M | 71.62M | 72.45M | 121.97M | 102.43M |
| Total Debt | 289.44M | 37.76M | 271.45M | 229.19M | 198.06M | 88.07M |
| Total Liabilities | 421.64M | 369.84M | 352.68M | 329.38M | 299.33M | 209.13M |
| Stockholders Equity | -9.73M | 13.69M | -29.61M | -6.78M | 45.19M | 95.23M |
Cash Flow | ||||||
| Free Cash Flow | 55.38M | 27.93M | -37.85M | -49.29M | -103.42M | -96.62M |
| Operating Cash Flow | 56.61M | 28.63M | -36.98M | -47.02M | -102.89M | -95.53M |
| Investing Cash Flow | -938.00K | -696.00K | 4.88M | -6.00M | 34.46M | 97.96M |
| Financing Cash Flow | 6.69M | 11.39M | 36.17M | -1.61M | 127.47M | 27.25M |
Xeris Pharmaceuticals Technical Analysis
Negative
8.74
Price Trends
8.41
Negative
7.42
Positive
7.05
Positive
Market Momentum
<0.01
Positive
33.75
Neutral
27.61
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XERS, the sentiment is Negative. The current price of 8.74 is above the 20-day moving average (MA) of 8.54, above the 50-day MA of 8.41, and above the 200-day MA of 7.05, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 33.75 is Neutral, neither overbought nor oversold. The STOCH value of 27.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for XERS.
Xeris Pharmaceuticals Risk Analysis
Xeris Pharmaceuticals disclosed 83 risk factors in its most recent earnings report. Xeris Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Xeris Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $1.56B | -87.33 | -426.33% | ― | 36.33% | 54.68% | |
58 Neutral | $2.09B | -13.92 | -72.07% | ― | -69.78% | -106.07% | |
56 Neutral | $1.92B | -8.94 | -59.36% | ― | -86.20% | -476.63% | |
54 Neutral | $3.78B | -7.39 | -87.98% | ― | -55.34% | -23.18% | |
53 Neutral | $2.20B | -15.16 | -29.02% | ― | ― | -23.53% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $1.84B | -7.91 | -372.94% | ― | 222.65% | 35.43% |
* Healthcare Sector Average
XERS
Xeris Pharmaceuticals
7.71
-0.10
-1.28%
SNDX
Syndax Pharmaceuticals
19.84
4.11
26.13%
ZYME
Zymeworks
27.15
11.96
78.74%
RCUS
Arcus Biosciences
28.49
16.77
143.09%
STOK
Stoke Therapeutics
29.92
7.26
32.04%
RAPP
Rapport Therapeutics, Inc.
46.09
23.69
105.76%
Xeris Pharmaceuticals Corporate Events
Business Operations and StrategyFinancial DisclosuresProduct-Related Announcements
Xeris Highlights XP-8121 Strategy and Growth Roadmap
Positive
Sep 9, 2026
On September 9, 2026, Xeris Biopharma hosted an XP‑8121 program overview to outline its strategy for becoming what it calls the next great biopharmaceutical company. Executives highlighted strong commercial performance from Recorlev, Gvoke a...
Business Operations and StrategyPrivate Placements and Financing
Xeris Biopharma Eliminates 2028 Convertible Notes Via Exchanges
Positive
Jul 17, 2026
On July 15, 2026, Xeris Biopharma Holdings, Inc. completed privately negotiated exchange transactions with certain holders of its 8.00% Convertible Senior Notes due 2028, swapping approximately $23 million in principal amount of notes for about 5....
Business Operations and StrategyExecutive/Board Changes
Xeris Pharmaceuticals appoints new director and board chair
Positive
Jun 30, 2026
On June 29, 2026, Xeris’ board expanded from seven to eight members and appointed veteran biotech executive and pediatric endocrinologist Nerissa Kreher, M.D., as a Class III director effective July 1, 2026, with an initial equity package st...
Business Operations and StrategyPrivate Placements and Financing
Xeris Biopharma Announces Debt Reduction via Note Exchanges
Positive
Jun 11, 2026
On June 10, 2026, Xeris Biopharma Holdings, Inc. entered into privately negotiated exchange agreements with certain holders of its 8.00% Convertible Senior Notes due 2028, aiming to retire approximately $23 million in principal through a mix of ca...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.